Literature DB >> 20186385

[Interferon-alfa induced reactivation of sarcoidosis in a patient with chronic hepatitis C].

I Mederacke1, K Wursthorn, H Ho, M P Manns, H Wedemeyer.   

Abstract

The data on reactivation of sarcoidosis during treatment with interferon-alfa is unsatisfactory. We here report the case of a female patient with a history of sarcoidosis more than 20 years ago. Due to chronic hepatitis C the patient was treated with pegylated interferon-alfa and ribavirin. Beginning in the 32(nd) week, the patient developed a reactivation of sarcoidosis. The antiviral therapy was continued until week 48 without administration of systemic steroids. Six month after the end of antiviral treatment the sarcoidosis was in remission and the hepatitis C was cured.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20186385     DOI: 10.1007/s00108-009-2543-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  10 in total

1.  Löfgren's syndrome revisited: a study of 186 patients.

Authors:  J Mañá; C Gómez-Vaquero; A Montero; A Salazar; J Marcoval; J Valverde; F Manresa; R Pujol
Journal:  Am J Med       Date:  1999-09       Impact factor: 4.965

2.  National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002.

Authors:  Leonard B Seeff; Jay H Hoofnagle
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 3.  Sarcoidosis.

Authors:  Michael C Iannuzzi; Benjamin A Rybicki; Alvin S Teirstein
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

4.  Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis.

Authors:  N Keicho; K Kitamura; F Takaku; H Yotsumoto
Journal:  Chest       Date:  1990-11       Impact factor: 9.410

Review 5.  Treating viral hepatitis C: efficacy, side effects, and complications.

Authors:  M P Manns; H Wedemeyer; M Cornberg
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

Review 6.  Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature.

Authors:  Eva A Hurst; Theodora Mauro
Journal:  Arch Dermatol       Date:  2005-07

7.  Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

Authors:  Thomas Berg; Michael von Wagner; Samer Nasser; Christoph Sarrazin; Tobias Heintges; Tilman Gerlach; Peter Buggisch; Tobias Goeser; Jens Rasenack; Gerd R Pape; Wolfgang E Schmidt; Birgit Kallinowski; Hartwig Klinker; Ulrich Spengler; Peter Martus; Ulrich Alshuth; Stefan Zeuzem
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

Review 8.  Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases.

Authors:  Manuel Ramos-Casals; Juan Mañá; Norma Nardi; Pilar Brito-Zerón; Antoni Xaubet; José Maria Sánchez-Tapias; Ricard Cervera; Josep Font
Journal:  Medicine (Baltimore)       Date:  2005-03       Impact factor: 1.889

Review 9.  [Diagnostics and therapy of chronic hepatitis B and C].

Authors:  J Wiegand; J Mössner; H L Tillmann
Journal:  Internist (Berl)       Date:  2008-07       Impact factor: 0.743

Review 10.  Expert opinion on the treatment of patients with chronic hepatitis C.

Authors:  S Zeuzem; T Berg; B Moeller; H Hinrichsen; S Mauss; H Wedemeyer; C Sarrazin; D Hueppe; E Zehnter; M P Manns
Journal:  J Viral Hepat       Date:  2008-08-28       Impact factor: 3.728

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.